Home | Sitemap | Contact Us     Search Ranbaxy for  
  Quick Links
 
 
   
   
 
    
 
     
 
   
 
 


Home
Investor Relations > Financials > Cash Flow > Ranbaxy Laboratories Limited - Consolidated (Indian GAAP)
 

     
Cash Flow



Untitled Document

 

CONSOLIDATED CASH FLOW STATEMENT
FOR THE YEAR ENDED DECEMBER 31, 2006
   
Rs. in Million
   
2006
2005
A. CASH FLOW FROM OPERATING ACTIVITIES
  Net profit before exceptional items and minority interests
6510.34
1,611.70
  Adjustments for :
  Depreciation, amortization & impairment
1,842.88
1,444.52
  Assets written off
10.04
33.31
  Deferred employees' compensation
26.35
32.68
  Unrealised exchange gain
(270.74)
(221.54)
  Dividend income
(1.01)
(0.26)
  Profit on disposal of investments
(12.89)
  (Profit) / Loss on sale of fixed assets (Net)
(41.12)
26.62
  Provision for diminution in value of current investments
(2.36)
(11.07)
  Interest expense
1,036.32
671.16
  Interest income
(211.22)
(180.62)
  Amounts written off
60.48
82.07
  Provision for doubtful debts and advances
142.50
(223.09)
   
2,579.23
1,653.78
  Operating profit before working capital changes
9,089.57
3,265.48
  Adjustments for :
  Inventories
(2,491.50)
504.23
  Sundry debtors / receivables
(4,667.75)
342.82
  Loans and advances
(537.58)
160.00
  Trade / Other payables
150.07
(1,135.05)
  Other current assets
3,055.00
(618.18)
   
(4,491.76)
(746.18)
  Net cash generated from operating activities before exceptional items
4,597.81
2,519.30
  Exceptional item : Interest in Joint venture written off
(121.80)
  Direct taxes paid (Net of refunds)
694.56
(360.27)
  Net cash from operating activities after exceptional items
5,292.37
2,037.23
B. CASH FLOW FROM INVESTING ACTIVITIES
  Purchase of fixed assets / capital works-in-progress
(4,358.14)
(9,274.60)
  Consideration received from discontinued business
-
1,236.10
  Sale of fixed assets
156.18
197.73
  Purchase of investments
(202.76)
  Sale proceeds of investments
27.38
  Investment in Subsidiary Company
(15,784.01)
(622.70)
  Investment in Joint Ventures
(99.08)
  Short term deposit / secured loans
16.35
5.68
  Interest received
213.08
175.92
  Dividend received
1.01
0.26
  Net cash used in investing activities
(19,930.91)
(8,380.69)
C. CASH FLOW FROM FINANCING ACTIVITIES
  Proceeds from issue of capital (including premium)
63.32
135.53
  Minority interest
168.52
(14.57)
  Proceeds from bank and other borrowings (net)
217.90
11,622.30
  Proceeds from FCCB
19,553.60
  FCCB issue expenses
(227.50)
  Interest paid
(1,036.32)
(671.16)
  Dividend paid
(3,167.27)
(3,164.26)
  Tax on dividend
(444.20)
(447.52)
  Net cash from financing activities
15,128.05
7,460.32
  INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS
489.51
1,116.86
  Cash and cash equivalents at the beginning
2,373.71
1,256.85
  Cash and cash equivalents at the end
2,863.22
2,373.71
Notes :
  Cash and cash equivalents include :
  Cash and cheques in hand and remittances in transit
170.04
313.18
  With banks in :
  Current accounts [Net of dividend accounts Rs. 87.06 million
(Previous year Rs. 55.27 million)]
1,122.68
809.91
  Deposit accounts [Net of pledged Rs. 0.88 million (Previous year Rs. 1.05 million)]
1,570.50
1,250.62
   
2,863.22
2,373.71
This is the consolidated cash flow statement referred to in our report of even date

  On behalf of the  Board of Directors
 
For WALKER, CHANDIOK & CO
Chartered Accountants
TEJENDRA KHANNA
Chairman

VINOD CHANDIOK
Partner
Membership No. 10093


DR. BRIAN W. TEMPEST

Chief Mentor &
Executive Vice Chairman

MALVINDER MOHAN SINGH
CEO & Managing Director

 

ATUL SOBTI
Chief Operating Officer &
Whole-time Director

  RAM S. RAMASUNDAR
President & CFO

Place : Gurgaon
Dated : March 29, 2007


SUSHIL K. PATAWARI

Secretary